Michael Wang

3.5k total citations · 1 hit paper
79 papers, 1.7k citations indexed

About

Michael Wang is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Michael Wang has authored 79 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Hematology, 15 papers in Genetics and 11 papers in Surgery. Recurrent topics in Michael Wang's work include Hemophilia Treatment and Research (47 papers), Platelet Disorders and Treatments (20 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Michael Wang is often cited by papers focused on Hemophilia Treatment and Research (47 papers), Platelet Disorders and Treatments (20 papers) and Blood Coagulation and Thrombosis Mechanisms (16 papers). Michael Wang collaborates with scholars based in United States, Germany and Italy. Michael Wang's co-authors include Marilyn J. Manco‐Johnson, David L. Cooper, Tyler W. Buckner, Neil A. Goldenberg, Christine L. Kempton, Doris Quon, Brian R. Branchford, Andrew M. Donson, Nicholas K. Foreman and Michael H. Handler and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Journal of Immunology.

In The Last Decade

Michael Wang

73 papers receiving 1.7k citations

Hit Papers

A multicenter, open-label phase 3 study of emicizumab pro... 2019 2026 2021 2023 2019 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Wang United States 22 1.1k 367 250 239 210 79 1.7k
Lothar Huebsch Canada 21 674 0.6× 182 0.5× 112 0.4× 78 0.3× 159 0.8× 73 1.5k
Jayne S. Wilson United Kingdom 15 442 0.4× 159 0.4× 83 0.3× 217 0.9× 149 0.7× 27 1.2k
Frederiek F van Doormaal Netherlands 14 280 0.2× 166 0.5× 581 2.3× 245 1.0× 210 1.0× 19 1.4k
Nathan T. Connell United States 16 600 0.5× 232 0.6× 131 0.5× 61 0.3× 178 0.8× 68 1.2k
Michael Krämer Germany 31 1.4k 1.3× 534 1.5× 38 0.2× 693 2.9× 350 1.7× 103 2.9k
Suma Choorapoikayil Germany 18 233 0.2× 65 0.2× 79 0.3× 258 1.1× 261 1.2× 59 1.3k
Karynsa Cetin United States 13 141 0.1× 33 0.1× 243 1.0× 84 0.4× 294 1.4× 39 1.1k
Carolyn Hoppe United States 29 1.7k 1.5× 1.9k 5.2× 28 0.1× 272 1.1× 66 0.3× 79 2.3k
Rutger A. Middelburg Netherlands 22 592 0.5× 247 0.7× 22 0.1× 58 0.2× 74 0.4× 75 1.3k
Keith A. Betts United States 23 326 0.3× 110 0.3× 13 0.1× 192 0.8× 67 0.3× 129 2.0k

Countries citing papers authored by Michael Wang

Since Specialization
Citations

This map shows the geographic impact of Michael Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Wang more than expected).

Fields of papers citing papers by Michael Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Wang. The network helps show where Michael Wang may publish in the future.

Co-authorship network of co-authors of Michael Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Wang. A scholar is included among the top collaborators of Michael Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Wang. Michael Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lim, Juin Yau, Yu Gan, Hao Cai, et al.. (2025). Life Cycle Greenhouse Gas Emissions of Biogas Upgrading for Fuel Production. ACS Sustainable Chemistry & Engineering. 13(48). 20670–20681.
2.
Young, Guy, et al.. (2024). FVIII Exposure Analysis from the HAVEN 7 Study of Emicizumab in Infants with Severe Hemophilia A. Blood. 144(Supplement 1). 2589–2589.
3.
Santoro, Cristina, Beng Fuh, Phu-Quoc Lê, et al.. (2022). Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS. European Journal Of Haematology. 110(1). 77–87. 2 indexed citations
4.
Mahlangu, Johnny, Daniel R Malan, Silva Zupančić Šalek, et al.. (2022). A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British Journal of Haematology. 200(2). 229–239. 28 indexed citations
5.
Witkop, Michelle, et al.. (2021). Impact of haemophilia on patients with mild‐to‐moderate disease: Results from the P‐FiQ and B‐HERO‐S studies. Haemophilia. 27(S1). 8–16. 13 indexed citations
6.
Ng, Christopher J., Sharon Funk, Marilyn J. Manco‐Johnson, et al.. (2021). Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematologica. 144(6). 672–677. 1 indexed citations
7.
Santoro, Cristina, Beng Fuh, Phu-Quoc Lê, et al.. (2020). BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. European Journal Of Haematology. 105(2). 164–172. 4 indexed citations
8.
Croteau, Stacy E., Michael J. Callaghan, Joanna A. Davis, et al.. (2018). Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis. 2(3). 607–614. 13 indexed citations
11.
Buckner, Tyler W., Michael Wang, David L. Cooper, Neeraj N. Iyer, & Christine L. Kempton. (2017). Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence. Volume 11. 1745–1753. 18 indexed citations
12.
Wang, Michael, María Román, Pratima Chowdary, Doris Quon, & Kim Schafer. (2016). Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients. Blood Coagulation & Fibrinolysis. 27(7). 737–744. 20 indexed citations
13.
Bishop, Claire, et al.. (2015). Mass Effect : Art and the Internet in the Twenty-First Century. MIT Press eBooks. 9 indexed citations
14.
Wang, Michael, et al.. (2015). Progesterone Is Not Effective in the Treatment of Traumatic Brain Injury. Neurosurgery. 76(4). N12–N13. 1 indexed citations
15.
Hancock, Hayley S., Michael Wang, Katja M. Gist, et al.. (2012). Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study. Cardiology in the Young. 23(3). 344–352. 25 indexed citations
16.
Branchford, Brian R., Peter M. Mourani, Lalit Bajaj, et al.. (2011). Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica. 97(4). 509–515. 77 indexed citations
17.
18.
Donson, Andrew M., Diane K. Birks, Valerie N. Barton, et al.. (2009). Immune Gene and Cell Enrichment Is Associated with a Good Prognosis in Ependymoma. The Journal of Immunology. 183(11). 7428–7440. 50 indexed citations
19.
Wang, Michael, Jane E. Libbey, Ikuo Tsunoda, & Robert S. Fujinami. (2003). Modulation of Immune System Function by Measles Virus Infection. II. Infection of B Cells Leads to the Production of a Soluble Factor That Arrests Uninfected B Cells in G 0 /G 1. Viral Immunology. 16(1). 45–55. 10 indexed citations
20.
Wang, Michael, Taru Hays, Vinod Balasa, et al.. (2003). Low-Dose Tissue Plasminogen Activator Thrombolysis in Children. Journal of Pediatric Hematology/Oncology. 25(5). 379–386. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026